February 21, 2025

Environmental vs. Genetic Risk in Aging and Mortality

Researchers quantify the exposome's greater impact on aging and mortality risk compared with genetic predisposition, identifying 25 key environmental risk factors.

Conexiant

February 21, 2025

Lung-MAP 3.0: Simplifying the Process to Meet Patients’ Needs

The Lung Cancer Master Protocol (Lung-MAP) is an innovative clinical trial designed to efficiently address the unmet needs of patients with advanced non–small cell lung cancer (NSCLC) following front-...

The ASCO Post

February 20, 2025

NY Sues Major Vape Distributors Over Youth Marketing

Attorney General Letitia James files lawsuit against 13 e-cigarette companies for allegedly targeting minors with flavored nicotine products, seeking hundreds of millions in damages and penalties.

Conexiant

February 14, 2025

eNRGy Trial: Zenocutuzumab for NRG1 Gene Fusion–Positive Solid Tumors

Treatment with the HER2 × HER3 bispecific antibody zenocutuzumab-zbco appeared to be safe and active in patients with advanced NRG1 gene fusion–positive solid tumors.

The ASCO Post

February 14, 2025

Study: Patients Trust Female Docs Less

Study findings and an interview with the lead investigator.

Conexiant

February 12, 2025

Forty-Minute Point-of-Care Lung Cancer Test

Biosensor enables early detection of lung cancer biomarkers

The Pathologist

February 11, 2025

H pylori: A Hidden Cancer Risk?

Microbial infections like H. pylori drive inflammation, oxidative DNA damage, and immune suppression, fueling cancer initiation and progression.

Conexiant

February 04, 2025

Predicting Response to KRAS G12C Inhibitors in NSCLC

Investigators discovered that measuring the interaction between the RAS and RAF proteins could provide valuable insights into the effectiveness of treatments in patients with KRAS G12C–mutated NSCLC.

The ASCO Post

January 29, 2025

Neoadjuvant Nivolumab/Ipilimumab vs Chemotherapy in Resectable NSCLC

In the phase III CheckMate 816 trial reported in the Journal of Clinical Oncology by Awad et al, researchers reported an exploratory analysis of the comparison of neoadjuvant nivolumab/ipilimumab vs c...

The ASCO Post